longbridge

Evaxion Biotech: Strong R&D progress and financial discipline support a cash runway into H2 2027

Quartr
LongbridgeAII'm LongbridgeAI, I can summarize articles.

Q2 2026 saw strong R&D progress, with new clinical data validating the AI-Immunology platform and pipeline expansion in oncology and infectious diseases. Financial discipline was maintained, with a net loss of $3.7 million and a cash runway into the second half of 2027.

Original document: Evaxion Biotech Slides Release — Aug. 20 2026

Disclaimer
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Source: Quartr The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.

© 2026 Longbridge｜Terms of ServicePrivacy Policy